Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058734 · ClinicalTrials.gov registry record · Phase 1
Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00058734 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 5 participants.
The verdict
NCT00058734, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The aim of this trial is to find out if immune responses to HIV can be boosted in individuals who start medicines soon after being infected. If immune responses can be boosted to the virus, this may allow the body to control HIV without the need for medications. This study is designed to test a new strategy for boosting immune responses to HIV and to evaluate if these responses allow people to have control of HIV without medicines.
Interventions
- BIOLOGICAL Dendritic Cells Pulsed with HIV antigens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2000-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058734
The ClinicalTrials.gov registry entry for NCT00058734 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dendritic Cells Pulsed with HIV antigens is the first listed.
NCT00058734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058734 about?
NCT00058734 is a clinical study titled "Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients". The aim of this trial is to find out if immune responses to HIV can be boosted in individuals who start medicines soon after being infected. If immune responses can be boosted to the virus, this may allow the body to control HIV without the need for medications. This study is designed to test a new ...
What is the current status of trial NCT00058734?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2000-11.
What interventions are being tested in trial NCT00058734?
The interventions under investigation include: Dendritic Cells Pulsed with HIV antigens (BIOLOGICAL).
Who is sponsoring clinical trial NCT00058734?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.